Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study
Authors:
- 1 June 2006
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (6) , 785-790
Abstract
Background: Osteonecrosis is common in systemic lupus erythematosus (SLE) and often disabling. The role of glucocorticoids in its development is well known. Objective: To explore other possible risk factors for osteonecrosis in SLE. Methods: A nested matched case–control study undertaken in the context of a large, longitudinal, multiethnic lupus cohort (LUMINA), currently formed of 571 SLE patients meeting American College of Rheumatology criteria. All those developing symptomatic osteonecrosis after the diagnosis of SLE were considered cases. Two controls matched for age, disease duration, ethnicity, and centre were selected for each case. Cases and controls were compared by univariable analyses using selected variables. Variables with pResults: 32 cases were identified and 59 matched controls selected (in five cases only one control could be found). By univariable analyses, both groups were largely comparable for socioeconomic-demographic, clinical, and laboratory variables. Cases were less exposed to hydroxychloroquine (as assessed by the percentage of exposure time) (p = 0.026), used higher doses of glucocorticoids (average and highest doses) (p = 0.011 and 0.001, respectively), and received cytotoxic drugs more often (p = 0.015). In the multivariable analyses only cytotoxic drug use (both models) and the highest dose of glucocorticoids remained associated with the occurrence of osteonecrosis. Conclusions: Cytotoxic drug use is a risk factor for the development of symptomatic osteonecrosis in SLE patients, along with glucocorticoids. No definite protective factors were identified.Keywords
This publication has 46 references indexed in Scilit:
- Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatmentAnnals of the Rheumatic Diseases, 2001
- Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohortLupus, 1999
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDLClinical and Experimental Immunology, 1995
- A vascular Osteonecrosis in Patients with SLE: Relation to Corticosteroid Therapy and Anticardiolipin AntibodiesLupus, 1994
- Avascular necrosis of boneCurrent Opinion in Rheumatology, 1990
- Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities.Annals of the Rheumatic Diseases, 1989
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- Ischemic Bone Necrosis in Systemic Lupus Erythematosus I. THE EARLY DIAGNOSIS OF ISCHEMIC NECROSIS OF BONEMedicine, 1980
- OSTEONECROSIS AFTER CHEMOTHERAPYThe Lancet, 1978